KBC Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

KBC Group’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,114	Closed	-$86K	–	1859
2024 Q2	$86K	Buy	2,114 +569	+37%	+$23.7K	﹤0.01%	1261
2024 Q1	$65K	Sell	1,545 -523	-25%	-$22K	﹤0.01%	1389
2023 Q4	$88K	Buy	2,068 +953	+85%	+$27.4K	﹤0.01%	1135
2023 Q3	$24K	Buy	+1,115	New	+$27.9K	﹤0.01%	1860

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

KBC Group's CERE Position: Q3 2024 in Review

KBC Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 2,114 shares — an estimated $86K sold.

KBC Group first reported a position in CERE in Q3 2023 and held it in 4 quarters. The position peaked at $88K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

KBC Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
KBC Group sold 2,114 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $86K.
KBC Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2023 and held it in 4 quarters.
KBC Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $88K in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on KBC Group's 13F filing for Q3 2024, filed 6 Nov 2024.